TY - JOUR
T1 - Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination
AU - Lindesmith, Lisa C.
AU - McDaniel, Jonathan R.
AU - Changela, Anita
AU - Verardi, Raffaello
AU - Kerr, Scott A.
AU - Costantini, Veronica
AU - Brewer-Jensen, Paul D.
AU - Mallory, Michael L.
AU - Voss, William N.
AU - Boutz, Daniel R.
AU - Blazeck, John J.
AU - Ippolito, Gregory C.
AU - Vinje, Jan
AU - Kwong, Peter D.
AU - Georgiou, George
AU - Baric, Ralph S.
N1 - Publisher Copyright:
© 2019 The Author(s)
PY - 2019/6/18
Y1 - 2019/6/18
N2 - Rapidly evolving RNA viruses, such as the GII.4 strain of human norovirus (HuNoV), and their vaccines elicit complex serological responses associated with previous exposure. Specific correlates of protection, moreover, remain poorly understood. Here, we report the GII.4-serological antibody repertoire—pre- and post-vaccination—and select several antibody clonotypes for epitope and structural analysis. The humoral response was dominated by GII.4-specific antibodies that blocked ancestral strains or by antibodies that bound to divergent genotypes and did not block viral-entry-ligand interactions. However, one antibody, A1431, showed broad blockade toward tested GII.4 strains and neutralized the pandemic GII.P16-GII.4 Sydney strain. Structural mapping revealed conserved epitopes, which were occluded on the virion or partially exposed, allowing for broad blockade with neutralizing activity. Overall, our results provide high-resolution molecular information on humoral immune responses after HuNoV vaccination and demonstrate that infection-derived and vaccine-elicited antibodies can exhibit broad blockade and neutralization against this prevalent human pathogen. Human norovirus (HuNoV) is a leading cause of gastroenteritis. Lindesmith et al. identify circulating serum antibodies following experimental HuNoV vaccination in humans and map them to viral epitopes. One antibody recognizes a neutralizing epitope conserved across three decades of pandemic strains and neutralizes virus in vitro, demonstrating that vaccination can elicit pandemic-strain neutralizing antibody responses in some individuals.
AB - Rapidly evolving RNA viruses, such as the GII.4 strain of human norovirus (HuNoV), and their vaccines elicit complex serological responses associated with previous exposure. Specific correlates of protection, moreover, remain poorly understood. Here, we report the GII.4-serological antibody repertoire—pre- and post-vaccination—and select several antibody clonotypes for epitope and structural analysis. The humoral response was dominated by GII.4-specific antibodies that blocked ancestral strains or by antibodies that bound to divergent genotypes and did not block viral-entry-ligand interactions. However, one antibody, A1431, showed broad blockade toward tested GII.4 strains and neutralized the pandemic GII.P16-GII.4 Sydney strain. Structural mapping revealed conserved epitopes, which were occluded on the virion or partially exposed, allowing for broad blockade with neutralizing activity. Overall, our results provide high-resolution molecular information on humoral immune responses after HuNoV vaccination and demonstrate that infection-derived and vaccine-elicited antibodies can exhibit broad blockade and neutralization against this prevalent human pathogen. Human norovirus (HuNoV) is a leading cause of gastroenteritis. Lindesmith et al. identify circulating serum antibodies following experimental HuNoV vaccination in humans and map them to viral epitopes. One antibody recognizes a neutralizing epitope conserved across three decades of pandemic strains and neutralizes virus in vitro, demonstrating that vaccination can elicit pandemic-strain neutralizing antibody responses in some individuals.
KW - antigenic seniority
KW - epitope mapping
KW - human monoclonal antibodies
KW - imprinting
KW - neutralizing antibodies
KW - norovirus
KW - original antigen sin
KW - serological repertoire
KW - vaccination
KW - x-ray crystallography
UR - http://www.scopus.com/inward/record.url?scp=85066877707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066877707&partnerID=8YFLogxK
U2 - 10.1016/j.immuni.2019.05.007
DO - 10.1016/j.immuni.2019.05.007
M3 - Article
C2 - 31216462
AN - SCOPUS:85066877707
SN - 1074-7613
VL - 50
SP - 1530-1541.e8
JO - Immunity
JF - Immunity
IS - 6
ER -